Organigram Global Inc SEC Filings

BT DE Investments Inc. and related BAT entities filed Amendment No. 7 to their Schedule 13D on Organigram Global Inc., updating details of a major strategic transaction and financing. They beneficially own 40,134,389 Common Shares, representing 29.7% of that class, and 13,794,163 Class A Preferred Shares, representing all Preferred Shares, based on 135,141,944 Common Shares outstanding as of February 5, 2026.

The filing describes Organigram’s agreement to acquire all remaining shares of Sanity Group GmbH, including BAT’s stake, with BAT electing to receive Organigram equity instead of cash. BAT is expected to receive 13,693,120 Preferred Shares as upfront consideration and 6,625,559 Common Shares as potential earnout consideration, assuming full earnout at a floor price of C$3.00 per share.

To help fund the acquisition and related costs, BT DE Investments agreed to a private placement, subscribing for 14,027,074 Shares at C$3.00 per share and exercising top-up rights for 9,897,356 Shares at C$2.335854 per share. A 30% ownership threshold caps BAT’s Common Share holding; any excess is issued as non‑voting, convertible Preferred Shares with a 7.5% annual accreting conversion rate until up to 49.0% of Common Shares could be issuable on conversion, subject to regulatory, shareholder and stock exchange approvals and existing investor rights agreements.

Organigram Global Inc. entered a detailed share sale and purchase agreement to acquire all 77,349 sale shares of Sanity Group GmbH. The deal uses a fixed enterprise value of EUR 130,000,000, adjusted for cash, debt, working capital and transaction-related items, plus an earn-out capped at EUR 120,000,000.

The preliminary fixed purchase price is EUR 110,550,000, funded by a EUR 78,000,000 cash closing payment and about EUR 29.3M in Organigram shares, with specific holdbacks and deductions. Additional true-up shares or cash repayments follow post-closing accounts. A parent guarantee backs German holding and purchaser payment obligations.

The earn-out depends on post-closing financial performance and net cash, can be reduced for lower net cash, and is partly settled in cash and partly in Organigram common and preference shares, with ownership caps and regulatory conditions for key seller BAT. The agreement also sets governance, non-competition, tax, warranty and intercompany conduct rules to protect earn-out calculations.

Organigram Global Inc. filed a Form 6-K to report a change of auditor. On February 5, 2026, the board decided to terminate PKF O’Connor Davies LLP as auditor and, on February 9, 2026, determined it would propose PricewaterhouseCoopers LLP as successor auditor at the next annual general meeting.

The predecessor auditor issued unqualified opinions on Organigram’s consolidated financial statements for the years ended September 30, 2025 and 2024, but gave an adverse opinion on the effectiveness of internal control over financial reporting for those years due to material weaknesses. The notice states there have been no reportable events under National Instrument 51-102, and both PKF O’Connor Davies and PwC provided letters agreeing with the company’s descriptions of the change.

Organigram Global Inc. announced a C$65.2 million private placement from British American Tobacco’s subsidiary BAT to help fund its proposed acquisition of German cannabis company Sanity Group. BAT will subscribe for 14,027,074 shares at C$3.00 and exercise top-up rights for 9,897,356 shares at about C$2.34.

To keep BAT’s voting stake at or below 30% of Organigram’s common shares, much of the investment will be in non-voting Class A convertible preferred shares, initially convertible one-for-one and accreting at 7.5% per year until BAT and affiliates could hold up to 49% on a partially diluted basis. Based on 135,141,944 common shares outstanding, BAT is expected to receive 2,353,379 common shares and 21,571,051 preferred shares from the private placement.

Closing of both the acquisition and the financing depends on shareholder approval, Toronto Stock Exchange approval, and other regulatory clearances, including German foreign investment review. Disinterested shareholders must approve the related-party transaction under TSX rules and a "majority of the minority" vote is required under MI 61-101. The company plans to seek approvals at a March 30, 2026 meeting.

Organigram Global Inc. is expanding into Europe with a definitive deal to acquire Germany-based Sanity Group, a fast-growing medical and recreational cannabis company. Organigram will pay upfront consideration of €113.4 million, split between €80.0 million in cash and €33.4 million in Organigram shares, with potential additional earnout payments of up to €113.8 million based on Sanity’s performance.

The structure implies a total potential valuation of up to €250.0 million. Sanity’s net revenue grew from €9 million in 2023 to €60 million in 2025, with gross margins improving from 15% to 47%, and the business generated positive EBITDA in 2025. Organigram expects the deal to be financially accretive and to create a vertically integrated European hub, adding leadership positions in both Canada and the growing German medical cannabis market.

The cash portion will be funded by Organigram’s cash on hand, a new credit facility of up to $60 million with ATB Financial and lenders, and an expected C$65.2 million equity investment from British American Tobacco through a private placement and top-up rights. Closing is targeted for the second quarter of 2026, subject to shareholder approvals, TSX and German regulatory clearances, and completion of the financing arrangements.

Organigram Global Inc. reported strong growth for the quarter ended December 31, 2025, with net revenue rising to $63,538 from $42,730 a year earlier, driven by higher Canadian recreational and international sales and contributions from the Motif acquisition.

Gross margin before fair value adjustments improved to $23,517, a 37% margin, while adjusted gross margin reached $23,855 or 38%. Adjusted EBITDA increased to $5,265 from $1,410, and net income swung to a profit of $19,969 versus a prior-year loss.

The company ended the quarter with $62,966 in cash, restricted cash and short‑term investments and working capital of $162,494, but used $18,117 of free cash flow. Management guides for Fiscal 2026 net revenue above $300 million, higher adjusted gross margins than Fiscal 2025, higher adjusted EBITDA, and positive free cash flow with capital expenditures under $10,000.

Organigram held the #1 share of the Canadian recreational cannabis market as of December 2025 and is expanding internationally, supported by a $124.6 million follow‑on investment from BAT and the Jupiter Pool. However, a material weakness in internal control over financial reporting remains under remediation, and pending U.S. legislative changes could force a sale, wind‑down or restructuring of hemp‑derived THC activities by November 2026.

Organigram Global Inc. will report its first quarter fiscal 2026 results, for the period ended December 31, 2025, on Tuesday, February 10, 2026, before the market opens. The company will host a conference call that day at 8:00 a.m. Eastern Time for investors and analysts.

Participants must register online to receive personalized dial-in details and access codes, and a live webcast will also be available. A replay of the webcast will be posted on Organigram’s investor website within 24 hours and remain accessible for 90 days. The filing also reiterates the company’s cannabis-focused operations in Canada and includes standard forward-looking statement cautions.

GLOBAL INC. has set key dates for its upcoming annual and special meeting of security holders. The meeting will be held on March 30, 2026, and holders of common shares on record as of February 23, 2026 will be entitled to receive notice and vote.

The meeting will cover both regular annual business and special matters. Notice-and-access will not be used for either registered or beneficial shareholders, and the issuer will pay for delivery of proxy-related materials to objecting beneficial owners.

Organigram Global Inc., a Canadian cannabis company listed on the TSX and Nasdaq under the symbol “OGI”, filed its annual report on Form 40-F as a foreign private issuer using IFRS.

The report notes 134,461,029 common shares outstanding as of the fiscal year ended September 30, 2025 and incorporates audited consolidated financial statements, management’s discussion and analysis, and an annual information form by reference.

Management determined that the company’s disclosure controls and internal control over financial reporting were not effective as of September 30, 2025 because of material weaknesses, and the independent auditor issued an adverse opinion on the effectiveness of ICFR.

The filing outlines remediation steps completed in Q4 Fiscal 2025, including engaging internal control specialists, hiring a VP of Information Technology, dedicating resources to review third‑party service organization reports and remediating certain IT general controls, and describes the board’s independent audit, compensation, governance and investment committees, code of ethics and alignment with TSX and applicable Nasdaq corporate governance standards.